Leerink Partners analyst Puneet Souda maintained a Buy rating on Natera (NASDAQ:NTRA) on Monday, setting a price target of $160, which is approximately 55.52% above the present share price of $102.88.
Souda expects Natera to post earnings per share (EPS) of -$0.74 for the second quarter of 2021.
The current consensus among 9 TipRanks analysts is for a Strong Buy rating of shares in Natera, with an average price target of $140.13.
The analysts price targets range from a high of $160 to a low of $125.
In its latest earnings report, released on 03/31/2021, the company reported a quarterly revenue of $152.32 million and a net profit of -$63.02 million. The company's market cap is $9.05 billion.
According to TipRanks.com, Leerink Partners analyst Puneet Souda is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 19.5% and a 61.67% success rate.
Natera, Inc. engages in the discovery, development, and commercialization of genetic testing services. It offers Panorama Non-Invasive Prenatal Test, Horizon Carrier Screening, Spectrum Pre-implantation Genetic Screening and Spectrum Pre-implantation Genetic Diagnosis, Anora Products of Conception and Non-Invasive Paternity Testing. The company was founded by Matthew Rabinowitz and Jonathan Sheena in November 2003 and is headquartered in San Carlos, CA.